Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”

Pazopanib is an oral angiogenesis inhibitor, currently approved for treatment of metastatic renal cell carcinoma (mRCC) and soft tissue sarcoma. The present study analyzed the outcomes of pazopanib in first-line treatment of mRCC, in a single Italian cancer center. In the light of the retrospective,...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Pharmacol
Main Authors: Cecere, Sabrina C., Rossetti, Sabrina, Cavaliere, Carla, Della Pepa, Chiara, Di Napoli, Marilena, Crispo, Anna, Iovane, Gelsomina, Piscitelli, Raffaele, Sorrentino, Domenico, Ciliberto, Gennaro, Maiolino, Piera, Muto, Paolo, Perdonà, Sisto, Berretta, Massimiliano, Pignata, Sandro, Facchini, Gaetano, D'Aniello, Carmine
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2016
Assuntos:
Pharmacology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5005368/
https://ncbi.nlm.nih.gov/pubmed/27630568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2016.00287
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares